This concurs with discussions triggered by now established non-biopsy diagnosis of cardiac wild-type transthyretin (ATTRwt) amyloidosis [19] and treatment options that have been approved [20] or are in the advanced stage of clinical investigation (e.g. NCT04136171, NCT03997383). This evidence concerns the gene TTR and amyloidosis.